Cargando…

Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE(®) system

OBJECTIVES: Cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) are well‐established in research settings, but their use in routine clinical practice remains a largely unexploited potential. Here, we examined the relationship between CSF biomarkers, measured by a fully automated im...

Descripción completa

Detalles Bibliográficos
Autores principales: Nojima, Hisashi, Ito, Satoshi, Kushida, Akira, Abe, Aki, Motsuchi, Wataru, Verbel, David, Vandijck, Manu, Jannes, Geert, Vandenbroucke, Ina, Aoyagi, Katsumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9735374/
https://www.ncbi.nlm.nih.gov/pubmed/36321325
http://dx.doi.org/10.1002/acn3.51681
_version_ 1784846749127409664
author Nojima, Hisashi
Ito, Satoshi
Kushida, Akira
Abe, Aki
Motsuchi, Wataru
Verbel, David
Vandijck, Manu
Jannes, Geert
Vandenbroucke, Ina
Aoyagi, Katsumi
author_facet Nojima, Hisashi
Ito, Satoshi
Kushida, Akira
Abe, Aki
Motsuchi, Wataru
Verbel, David
Vandijck, Manu
Jannes, Geert
Vandenbroucke, Ina
Aoyagi, Katsumi
author_sort Nojima, Hisashi
collection PubMed
description OBJECTIVES: Cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) are well‐established in research settings, but their use in routine clinical practice remains a largely unexploited potential. Here, we examined the relationship between CSF biomarkers, measured by a fully automated immunoassay platform, and brain β‐amyloid (Aβ) deposition status confirmed by amyloid positron emission tomography (PET). METHODS: One hundred ninety‐nine CSF samples from clinically diagnosed AD patients enrolled in a clinical study and who underwent amyloid PET were used for the measurement of CSF biomarkers Aβ 1–40 (Aβ40), Aβ 1–42 (Aβ42), total tau (t‐Tau), and phosphorylated tau‐181 (p‐Tau181) using the LUMIPULSE system. These biomarkers and their combinations were compared to amyloid PET classification (negative or positive) using visual read assessments. Several combinations were also analyzed with a multivariable logistic regression model. RESULTS: Aβ42, t‐Tau, and p‐Tau181, and the ratios of Aβ42 with other biomarkers had a good diagnostic agreement with amyloid PET imaging. The multivariable logistic regression analysis showed that amyloid PET status was associated with Aβ40 and Aβ42, but other factors, such as MMSE, sex, t‐Tau, and p‐Tau181, did not significantly add information to the model. CONCLUSIONS: CSF biomarkers measured with the LUMIPULSE system showed good agreement with amyloid PET imaging. The ratio of Aβ42 with the other analyzed biomarkers showed a higher correlation with amyloid PET than Aβ42 alone, suggesting that the combinations of biomarkers could be useful in the diagnostic assessment in clinical research and potentially in routine clinical practice.
format Online
Article
Text
id pubmed-9735374
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-97353742022-12-12 Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE(®) system Nojima, Hisashi Ito, Satoshi Kushida, Akira Abe, Aki Motsuchi, Wataru Verbel, David Vandijck, Manu Jannes, Geert Vandenbroucke, Ina Aoyagi, Katsumi Ann Clin Transl Neurol Research Articles OBJECTIVES: Cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) are well‐established in research settings, but their use in routine clinical practice remains a largely unexploited potential. Here, we examined the relationship between CSF biomarkers, measured by a fully automated immunoassay platform, and brain β‐amyloid (Aβ) deposition status confirmed by amyloid positron emission tomography (PET). METHODS: One hundred ninety‐nine CSF samples from clinically diagnosed AD patients enrolled in a clinical study and who underwent amyloid PET were used for the measurement of CSF biomarkers Aβ 1–40 (Aβ40), Aβ 1–42 (Aβ42), total tau (t‐Tau), and phosphorylated tau‐181 (p‐Tau181) using the LUMIPULSE system. These biomarkers and their combinations were compared to amyloid PET classification (negative or positive) using visual read assessments. Several combinations were also analyzed with a multivariable logistic regression model. RESULTS: Aβ42, t‐Tau, and p‐Tau181, and the ratios of Aβ42 with other biomarkers had a good diagnostic agreement with amyloid PET imaging. The multivariable logistic regression analysis showed that amyloid PET status was associated with Aβ40 and Aβ42, but other factors, such as MMSE, sex, t‐Tau, and p‐Tau181, did not significantly add information to the model. CONCLUSIONS: CSF biomarkers measured with the LUMIPULSE system showed good agreement with amyloid PET imaging. The ratio of Aβ42 with the other analyzed biomarkers showed a higher correlation with amyloid PET than Aβ42 alone, suggesting that the combinations of biomarkers could be useful in the diagnostic assessment in clinical research and potentially in routine clinical practice. John Wiley and Sons Inc. 2022-11-02 /pmc/articles/PMC9735374/ /pubmed/36321325 http://dx.doi.org/10.1002/acn3.51681 Text en © 2022 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Articles
Nojima, Hisashi
Ito, Satoshi
Kushida, Akira
Abe, Aki
Motsuchi, Wataru
Verbel, David
Vandijck, Manu
Jannes, Geert
Vandenbroucke, Ina
Aoyagi, Katsumi
Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE(®) system
title Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE(®) system
title_full Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE(®) system
title_fullStr Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE(®) system
title_full_unstemmed Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE(®) system
title_short Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE(®) system
title_sort clinical utility of cerebrospinal fluid biomarkers measured by lumipulse(®) system
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9735374/
https://www.ncbi.nlm.nih.gov/pubmed/36321325
http://dx.doi.org/10.1002/acn3.51681
work_keys_str_mv AT nojimahisashi clinicalutilityofcerebrospinalfluidbiomarkersmeasuredbylumipulsesystem
AT itosatoshi clinicalutilityofcerebrospinalfluidbiomarkersmeasuredbylumipulsesystem
AT kushidaakira clinicalutilityofcerebrospinalfluidbiomarkersmeasuredbylumipulsesystem
AT abeaki clinicalutilityofcerebrospinalfluidbiomarkersmeasuredbylumipulsesystem
AT motsuchiwataru clinicalutilityofcerebrospinalfluidbiomarkersmeasuredbylumipulsesystem
AT verbeldavid clinicalutilityofcerebrospinalfluidbiomarkersmeasuredbylumipulsesystem
AT vandijckmanu clinicalutilityofcerebrospinalfluidbiomarkersmeasuredbylumipulsesystem
AT jannesgeert clinicalutilityofcerebrospinalfluidbiomarkersmeasuredbylumipulsesystem
AT vandenbrouckeina clinicalutilityofcerebrospinalfluidbiomarkersmeasuredbylumipulsesystem
AT aoyagikatsumi clinicalutilityofcerebrospinalfluidbiomarkersmeasuredbylumipulsesystem